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Juvenile Dermatomyositis (JDM) is a systemic, inflamma-
tory, idiopathic disease, mainly affecting the skin and the
muscles, starting before the age of 16 with an incidence
around one case per million children. Some patients dis-
play typical features of JDM without skin involvement or
even without muscle involvement, however both tissues
are affected over time in most cases. Diagnosis criteria
have been established by Bohan and Peter 35 years ago,
based on the presence of typical skin rash and proximal
muscle involvement. Other conditions have to be rulled
out before making a diagnosis of JDM, such us other
connective tissue diseases, polymyositis, infectious/post-
infectious myositis, genetic diseases, metabolic or drug-
induced myopathies. Unlike adult-onset dermatomyositis,
JDM is exceptionnaly associated with a malignant disease.
JDM may also affect several organs including the
lungs and the digestive tract. In a subset of patients, glu-
cose intolerance, lipodystrophia and/or calcinosis
develop. Delay in treatment initiation or inadequate
treatment may favour diffuse, debilitating calcinosis.
JDM patients have to be referred to reference pediatric
centers with a multidisciplinary team to properly assess
disease activity, disease-related damage (including low
bone density in most cases) and define the best treatment.
Long-lasting corticosteroid therapy remains the gold stan-
dard, together with physiotherapy. Physiotherapists often
play an important rule not only through their participation
to patients care but also by assessing disease activity at
each stage, using several tools including CMAS and MMT
assessment of muscle strength. Other tools have been
developed to assess extra-muscular disease and disease-
related damage. Patients quality of life also needs to be
properly assessed. Several collaborative efforts have been
conducted to improve the way we assess patients health
and response to treatment.
Most patient respond to treatment, relapses are frequent
but a complete disease remission is achieved in most cases
before adulthood, with or without sequellae. Ongoing clin-
ical trials are assessing the effect of several immunosup-
pressive and immunomodulatory drugs; preliminary
results from a PRINTO international trial suggest that
both methotrexate and cyclosporine may help controlling
the disease, reducing the rate of early flares and may
hence have a corticosteroid-sparing effect. On the short
term, methotrexate seems better tolerated. Some prelimin-
ary data suggest that other drugs may also be of interest.
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